Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

GB:0ACH Stock Latest News

The FlyMedinCell downgraded to Hold from Buy at Kepler Cheuvreux2w ago

Company AnnouncementsMedinCell Delays Half-Year 2026 Earnings Release by One Day2w ago
Company AnnouncementsMedinCell Bolsters Finances With €41.8 Million in Non-Dilutive Funding2w ago
Company AnnouncementsMedinCell Halts Euronext Trading Ahead of Market-Sensitive Announcement3w ago
Company AnnouncementsMedincell Shares Suspended on Euronext as Long-Acting Injectable Portfolio Advances3w ago

MedinCell Updates Share Capital and Voting Rights as BEPO Platform Gains Global Traction

Company AnnouncementsMedinCell Updates Share Capital and Voting Rights as BEPO Platform Gains Global Traction4w ago

Company AnnouncementsMedincell Extends Postal Voting Window as Flood Alerts Hit Hérault1M ago

The FlyMedinCell initiated with an Outperform at Oppenheimer1M ago

Company AnnouncementsMedinCell’s BEPO Platform Gains Momentum as Teva Unveils Strong Data for Long-Acting Antipsychotics1M ago
Company AnnouncementsMedinCell steps up investor outreach as long-acting injectable pipeline advances1M ago
Company AnnouncementsMedinCell Calls 2026 General Meeting, Bolsters Governance and Shareholder Engagement1M ago
Company AnnouncementsMedincell Strengthens Leadership with Appointment of New Chief Medical Officer2M ago

MedinCell to Present CNS Strategy at Piper Sandler Symposium

Company AnnouncementsMedinCell to Present CNS Strategy at Piper Sandler Symposium2M ago

Company AnnouncementsMedinCell Reports Updated Voting Rights as Long-Acting Injection Portfolio Expands2M ago

Company AnnouncementsMedincell Gains From Record UZEDY Sales and Progress of Olanzapine LAI3M ago

Company AnnouncementsMedinCell Files 2025/2026 Universal Registration Document With AMF3M ago
Company AnnouncementsMedinCell Earnings Call Signals Investment-Led Transition4M ago
RatingsMedinCell: EMA Acceptance and 2026 U.S. Approval Outlook for Olanzapine LAI Underpin Reiterated Buy and €33 Price Target5M ago
Company AnnouncementsMedinCell SA’s Earnings Call Highlights Growth and Strategic Milestones10M ago

MedinCell SA: Promising Growth in Long-Acting Injectable Market with Strategic Collaborations and Expanding Product Portfolio

RatingsMedinCell SA: Promising Growth in Long-Acting Injectable Market with Strategic Collaborations and Expanding Product Portfolio1y ago

RatingsMedinCell SA: Strategic Collaborations and Promising Developments Justify Buy Rating1y ago

RatingsMedinCell’s Promising Growth: Buy Rating Backed by UZEDY Expansion and TEV-44749 Progress1y ago